Skip to Content


In the US, Alirocumab (alirocumab systemic) is a member of the drug class PCSK9 inhibitors and is used to treat Cardiovascular Risk Reduction, High Cholesterol, High Cholesterol - Familial Heterozygous and High Cholesterol - Familial Homozygous.

US matches:



CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Lipid lowering agent

Lipid lowering agent for the treatment of homozygous familial hypercholesterolemia

Chemical Name

Immunoglobulin G1-kappa, anti-[Homo sapiensPCSK9 (propotein convertase subtilisin/kexin type 9)], Homo sapiensmonoclonal antibody;gamma1 haevy chain (1-447)[Homo sapiensVH (IGHV3-23*04 (89.80%) -(IGHD)-IGHJ2*01 [8.8.11](1-118) -IGHG1*01 CHS K2>del (119-44 (WHO)

Foreign Names

  • Alirocumabum (Latin)
  • Alirocumab (German)
  • Alirocumab (French)
  • Alirocumab (Spanish)

Generic Names

Brand Names

  • Praluent
    Sanofi, United Kingdom; Sanofi-Aventis, Germany


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.